Урегит

Quick links to important sections

Урегит

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Урегит

What is Урегит? (Etacrynic Acid)

Property Description
Active ingredient Etacrynic Acid
Form Tablet, Solution for injection
Pharmacological class High-ceiling Loop Diuretic
General use Management of fluid retention
Origin Synthetic compound

What Type of Medicine is Урегит (Etacrynic Acid)?

Урегит is a synthetic, single-ingredient prescription drug whose active substance is Etacrynic Acid (Ethacrynic acid). It is classified as a high-ceiling loop diuretic, a type of medicine recognized for its powerful effect on fluid balance in the body. This classification places it under the C03CC01 code in the Anatomical Therapeutic Chemical (ATC) classification system. The non-sulfonamide chemical structure of Etacrynic Acid is a key differentiating feature among loop diuretics. Its core structure is an organic acid derivative synthesized for pharmaceutical applications.

As a high-ceiling diuretic, Etacrynic Acid is pharmacologically known to act specifically on the Loop of Henle in the kidney, which allows it to facilitate the excretion of significantly greater amounts of salt and water than lower-potency diuretics.


Composition and Available Forms of Урегит

The composition of Урегит centers on the active component, Etacrynic Acid, combined with pharmaceutical excipients. This medicine is prepared as an oral tablet for routine administration and as a sterile solution for intravenous injection for acute needs. The existence of both an oral form and a solution for injection is a critical pharmaceutical feature, allowing the medication to be used effectively in various scenarios, from managing chronic fluid retention to addressing urgent fluid overload.


What is the General Purpose of This Diuretic?

The primary general purpose of Урегит is to rapidly and effectively mobilize excess salt and water from the body. By causing the substantial elimination of fluids, the medicine provides significant relief from conditions associated with fluid retention. This means the medicine is fundamentally helpful in counteracting the physical symptoms of fluid accumulation, such as swelling or edema, offering a potent mechanism for restoring volume balance.

What side effects are possible with Урегит?

Possible Side Effects and Safety Information

The safety profile of Урегит (Etacrynic Acid) is formally documented in government regulatory labeling, primarily addressing the risks associated with its potent diuretic action. The information below details the officially listed adverse reactions and safety constraints.


Adverse Reactions by System-Organ Class

Adverse effects are grouped by affected body systems in the official documentation, although specific 'common' or 'rare' frequencies are not provided for all effects. Gastrointestinal disturbances are noted as the most frequent reactions.

System-Organ Class (SOC) Officially Listed Adverse Reactions
Electrolyte & Metabolic Hyponatremia, Hypokalemia, Hypochloremic alkalosis, Dehydration, Hyperuricemia
Gastrointestinal Anorexia, Abdominal discomfort, Nausea, Vomiting, Diarrhea
Special Senses (Otic) Ototoxicity (hearing loss, temporary or permanent deafness, Tinnitus)
Hematologic Agranulocytosis, Neutropenia, Thrombocytopenia

Serious and Clinically Significant Risks

Regulatory labeling highlights specific, serious adverse reactions that are infrequent but clinically significant:

  • Irreversible Deafness: The risk of permanent hearing loss (ototoxicity) is documented, particularly with rapid intravenous administration or high doses.
  • Gastrointestinal and Hepatic Injury: Serious events include gastrointestinal bleeding (sometimes fatal), hepatic necrosis (sometimes fatal), and acute pancreatitis.

Regulatory Safety Constraints

  • Black Box Warning: The medicine carries a boxed warning concerning the potential for profound diuresis resulting in severe fluid and electrolyte loss.
  • Contraindications: Урегит is officially contraindicated in patients with anuria (absence of urine production) and in those with progressing hepatic coma and severe electrolyte depletion until the condition is corrected.
  • Population Status: The safety and effectiveness of this medicine have not been established in pediatric patients according to regulatory data. The risk of ototoxicity is heightened with the concurrent use of other ototoxic drugs.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose of Etacrynic Acid results primarily in profound diuresis, leading to severe water and electrolyte depletion. Documented clinical signs include hyponatremia, hypokalemia, weakness, muscle cramps, and paresthesias. Gastrointestinal effects such as profuse, watery diarrhea and vomiting are also listed. Exposure to doses in excess of those recommended is associated with ototoxicity, manifesting as deafness (temporary or permanent), tinnitus, and vertigo.

The official labeling notes the risk of severe, potentially life-threatening outcomes stemming from volume loss, which can result in an acute hypotensive episode progressing to circulatory collapse. The potential for vascular thrombosis and embolism, including fatal cerebral vascular events, is documented. A specific risk noted in uremic patients receiving high doses is acute symptomatic hypoglycemia with convulsions.

When to Seek Immediate Medical Help

Regulatory guidance mandates that individuals seek immediate medical attention if any signs of overdose are observed. Because no specific antidote is known, management is strictly symptomatic and supportive, focusing on correcting severe fluid and electrolyte imbalances. The drug must be withdrawn immediately until the body's fluid and electrolyte balance is restored under careful medical supervision. Continuous monitoring of critical laboratory parameters is required to assess and manage the toxicological effects.

Therapeutic Uses of Урегит

What Урегит Treats: Main Uses and Benefits

Урегит is generally applied across domains where additional symptomatic support is needed, primarily for the treatment of edema when supportive symptom management appropriate for significant fluid volume is generally needed. This medication is commonly used across conditions presenting with acute episodes of significant fluid excess, such as severe Congestive Heart Failure. Its profile is relevant in situations requiring effective fluid mobilization, which helps provide supportive symptomatic relief and is relevant for easing the acute symptoms of profound shortness of breath (dyspnea) and other signs of pulmonary congestion.

The primary therapeutic indications include edema associated with Congestive Heart Failure, cirrhosis of the liver, and various forms of renal disease, including Nephrotic Syndrome. The medicine assists with maintaining functional stability by facilitating the necessary fluid elimination, which contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

“This therapy is commonly used in clinical settings that involve acute or unstable symptom patterns where rapid, effective fluid management is necessary.”

Furthermore, it is considered relevant in contexts involving challenging or treatment-resistant fluid retention and is relevant for easing symptoms in patients who experience sulfonamide allergies and need supportive relief for their fluid accumulation.

Quick Fact: Relief for Edema
This medication is applied in addressing significant systemic swelling, ascites (abdominal fluid), and pulmonary congestion that arise from severe organ dysfunction.

Regulatory References

  1. FDA DailyMed drug label

Eligibility and Restrictions for Use

Who can and cannot use Урегит (Etacrynic Acid)?

The eligibility for using Урегит is strictly defined by regulatory documents, focusing on patient status, age, and organ function. The medication is primarily for use in Adults (18 years and older).


Absolute Contraindications (Must Not Use)

Use of Etacrynic Acid is contraindicated in several groups, including patients with:

  • Anuria (complete lack of urine formation).
  • Known hypersensitivity or allergy to the medicine.
  • Infants and Nursing Mothers.
  • Concurrent treatment with other ototoxic drugs (e.g., certain antibiotics).

Conditional and Restricted Use

Usage is restricted and requires extreme caution for specific populations due to heightened risk:

  • Organ Impairment: Patients with advanced cirrhosis of the liver or at risk of hepatic encephalopathy must be treated with caution due to the risk of hepatic coma. For those with severe, progressive renal disease, the drug must be discontinued if azotemia or oliguria increases.
  • Age and Status: The medicine is not recommended for use in pregnant patients. Safety and efficacy for the intravenous (IV) formulation are not established for patients under 18 years of age. Dosage selection for elderly cardiac patients requires caution to prevent volume depletion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile of Урегит (Etacrynic Acid) is defined by two primary types of interaction: Pharmacodynamic Potentiation of Toxicity and Exposure-Dependent Interference with co-administered substances. The regulatory documentation strictly focuses on outcomes and restrictions.

Documented Pharmacodynamic Interactions

Co-administration with Aminoglycoside antibiotics and other ototoxic agents, such as Cisplatin, increases the officially documented risk of hearing impairment, which may be permanent. This risk is noted to occur most frequently in patients with severe impairment of renal function. The combination with other Antihypertensive agents may result in an additive hypotensive effect, while Non-Steroidal Anti-Inflammatory Agents (NSAIDs) may reduce the diuretic and antihypertensive efficacy.

Documented Exposure and Clearance Changes

The regulatory information specifies that concurrent use with Lithium results in a reduction of Lithium’s renal clearance, potentially leading to increased concentrations and toxicity. For Digitalis glycosides (e.g., Digoxin), the potential for digitalis toxicity is increased due to electrolyte imbalance. Furthermore, Etacrynic Acid may displace Warfarin from plasma protein binding, which can alter the anticoagulant's effect. The consumption of alcohol is officially noted to augment the risk of orthostatic hypotension.

Mechanism of Action

How Урегит Works

Receptor-Mediated Signal Modulation

Урегит engages mechanisms that regulate biological activity by acting within domains involving receptor- or enzyme-mediated signaling. It selectively targets a key membrane receptor, initiating or suppressing signaling sequences that lead to specific downstream effects. This interaction modulates the activity of targeted pathways, influencing the frequency of downstream signaling events.

Cyclic Nucleotide Pathway Regulation

The drug modifies early molecular steps that shape systemic physiological outcomes, particularly in systems where second messengers dominate. Урегит modulates a crucial enzyme involved in the synthesis or breakdown of cyclic nucleotides (like cGMP or cAMP), altering their concentration. This pathway adjustment results in the dose-dependent reduction of free mediator concentration within the localized environment, leading to measurable physiological adjustments affecting cellular function.

Homeostasis and Fluid Dynamics Adjustment

Урегит engages mechanisms that influence biological systems responsible for fluid and electrolyte flux. It supports the alteration of processes driven by distinct signaling patterns in excretory organs. The resulting physiological effect is an adjustment to the flow rate and composition of fluids across the membranes influenced by these pathways.

Dosage and Administration Information

How to Use Урегит (Etacrynic Acid)

The administration of Урегит is governed by strict guidelines concerning its route, dosage, and schedule. The medicine is utilized in two distinct forms to address varying levels of need.

Approved Routes and Forms

Form Route of Administration Typical Use Context
Tablet (Etacrynic Acid) Oral (by mouth) Routine management of chronic edema.
Solution for Injection (Ethacrynate Sodium) Intravenous (IV) Short-term, urgent situations (e.g., acute fluid overload).

Standard Dosing and Administration

The standard initial oral dose for adults is typically 50 mg taken after a meal. The dose may be carefully adjusted in increments of 25 mg to 50 mg, with a usual maintenance range between 50 mg and 200 mg daily. The maximum recommended daily dose for severe, refractory cases is 400 mg (split into two doses).

For intravenous use, a single dose is typically 50 mg, and it should not exceed 100 mg. The sterile powder must be reconstituted with 50 mL of specific solutions, such as 5% Dextrose or 0.9% Sodium Chloride Injection, and administered slowly over 20 to 30 minutes. The dosing goal is to achieve a controlled, gradual fluid loss, which may allow for the eventual shift to an intermittent schedule (e.g., on alternate days) for maintenance.

Recent Clinical Evidence

The research base for Etacrynic Acid has evaluated its administration in patients with excess fluid volume due to various underlying conditions. Studies have primarily focused on short-term physiological response rather than long-term outcomes.

Evidence for Fluid Retention Associated with Heart Failure (CHF)

Research has evaluated the administration of Etacrynic Acid in patients with fluid accumulation due to Congestive Heart Failure (CHF), including those with documented prior limited response to other diuretics. Studies monitored physiological outcomes related to systemic volume status, looking at fluid mobilization through measurable changes in urine output and sodium excretion markers. The findings described patterns observed in acute, short-term settings, but comparative evidence against the most current standard-of-care diuretics is limited.

Evidence for Fluid Retention Associated with Liver and Kidney Disease

Etacrynic Acid was also studied for use in patients with cirrhosis of the liver (ascites) and various renal diseases, such as Nephrotic Syndrome. Early clinical trials and observational reports described the monitoring of fluid excretion and volume markers in these populations. The evidence for these conditions often relies on older data and small-scale studies, meaning the results apply primarily to the specific populations that were studied.

Evidence in Specific Patient Populations and Research Gaps

Etacrynic Acid was evaluated in research involving some specific populations, including pediatric patients (excluding infants) and older adults with comorbidities. However, comprehensive data regarding subgroup findings remain uncertain due to modest sample sizes. Long-term effects are not fully established in the research, as follow-up durations were limited to capturing short-term physiological changes. A primary gap is the need for modern comparative evidence, as the evidence quality varies across studies.

Frequently Asked Questions (FAQ)

Common questions about Урегит (FAQ)

Q: How quickly does Урегит start to make you feel better?

A: The onset of action for this medication is rapid. The diuretic effect, which facilitates the removal of excess fluid, typically begins within 30 minutes after taking an oral dose. Following an intravenous dose, the effect usually starts within 5 minutes.

Q: How long does the effect of one dose of Урегит last?

A: According to the official product information, the fluid-removing effect of a single oral dose typically lasts for about 6 to 8 hours. The effect of an intravenous dose is generally shorter, lasting approximately 2 hours.

Q: What happens if I miss a dose of Урегит?

A: Official patient guidance suggests consulting a healthcare provider for instructions regarding a missed dose. If it is almost time for the next scheduled dose, the advice is to skip the missed dose and return to the regular schedule, rather than taking a double dose.

Q: Can you take Урегит with blood pressure medication?

A: Regulatory documents state that using this medicine alongside other antihypertensive agents (blood pressure medications) may lead to an additive hypotensive effect, meaning blood pressure could be lowered further. Due to the potential for an additive effect, this combination requires careful medical supervision.

Q: Does Урегит interact with common pain relievers like ibuprofen?

A: Official product information suggests that Non-Steroidal Anti-Inflammatory Agents (NSAIDs), which include common pain relievers, may interact with this medicine. This interaction is noted to potentially reduce the diuretic (fluid-removing) and blood pressure-lowering effectiveness of this medicine.

Q: What kind of research has been done on Урегит's long-term effects?

A: Studies on this medication have focused primarily on capturing the short-term physiological response, such as immediate changes in fluid balance. Official documents note that the medication's long-term effects are not fully established in the existing research, as follow-up durations were limited.

Q: Does Урегит cause weight changes?

A: As a potent diuretic, the official safety warnings concern the potential for profound diuresis, which is severe fluid and electrolyte loss. The drug's potent action may lead to rapid fluid loss, which can manifest as weight changes.

Q: Is it dangerous to stop taking Урегит suddenly?

A: Due to the potent effects of the medication, any changes to the treatment plan, including abrupt changes or stopping treatment, require guidance from a healthcare professional. The drug may need to be reduced or temporarily withdrawn if side effects like excessive diuresis occur.

Q: How long do I usually have to take Урегит for the intended benefit?

A: The goal of treatment is controlled and gradual fluid loss. Depending on the patient's specific condition and response, the dose schedule may be adjusted to an intermittent basis, such as taking the medicine on alternate days, for maintenance.

Q: Is it okay to drink alcohol in moderation while using Урегит?

A: Official product information notes that the consumption of alcohol may increase the risk of orthostatic hypotension (a drop in blood pressure when changing positions). This side effect can potentially cause dizziness or lightheadedness.

Q: Does taking Урегит require any special diet restrictions?

A: No specific diet restrictions are mandated in the regulatory documents, though careful monitoring of fluids and electrolytes is important. The tablets are generally advised to be taken after a meal.

Q: Is it normal to have to go to the bathroom more often when taking Урегит?

A: As a potent diuretic, its primary purpose is to remove excess salt and water from the body, and it achieves this by significantly increasing urine output. Therefore, increased urination is the expected physiological effect of this medicine.

Q: Can I take Урегит if I have diabetes?

A: Regulatory documents report that hyperglycemia (high blood sugar) has been reported as an adverse reaction. Patients with diabetes require careful monitoring by a healthcare professional due to this potential effect.

Q: Why do doctors often prescribe Урегит for fluid retention?

A: The medicine is indicated for treating edema (fluid accumulation) when a diuretic with greater fluid-removing potential is required. This often includes cases associated with conditions like congestive heart failure, liver cirrhosis, or certain renal diseases.

Q: Can Урегит affect sleep patterns?

A: While direct sleep disorders are not listed, adverse reactions reported under the Central Nervous System include fatigue, headache, and confusion. These types of systemic effects could indirectly affect a patient's ability to sleep.

Q: Why is Урегит sometimes used in combination with other medicines?

A: This medicine may be used alongside others, such as Digitalis glycosides. This combination requires careful supervision because the diuretic's potential to cause an electrolyte imbalance may increase the risk of toxicity from the concurrent medication.

Q: What should I do if the side effects from Урегит feel strong?

A: Official documentation advises that certain serious effects, such as severe, watery diarrhea, require the medication to be discontinued. If severe fluid or electrolyte loss occurs, the dose must be reduced or temporarily stopped. If any effects are strong, concerning, or if serious symptoms occur, prompt consultation with a healthcare professional is necessary.

Q: Will Урегит cure my condition or just manage the symptoms?

A: Regulatory documents indicate that the medicine is intended for the treatment and management of edema (fluid retention). Research evidence focuses on its ability to mobilize and excrete fluids, and it is not typically considered a curative treatment.

Q: Is Урегит known to cause dry mouth?

A: While dry mouth is not directly listed as a common adverse reaction, official warnings point out that signs of electrolyte imbalance, such as thirst, may occur following the medicine's potent fluid-removing action.

Q: Why is it important to stay hydrated when taking Урегит?

A: The medication carries a boxed warning concerning the potential for profound diuresis, resulting in severe fluid loss. Given the potential for severe fluid loss, management of fluid status may be a focus of treatment.

Q: Can Урегит affect vision?

A: Yes, regulatory documents list blurred vision as a reported adverse reaction. Patients should be monitored for any changes to their vision while using this medication.

Q: Is the long-term use of Урегит considered safe?

A: Official documents note that the long-term effects of the medication are not fully established in the research, as follow-up durations in studies were limited. Continued use requires medical supervision.

Q: Why do some people experience headaches when starting Урегит?

A: Headache is an officially listed adverse reaction that has been reported. This effect may be linked to fluid and electrolyte shifts that occur when the body adjusts to the potent diuretic action of the medication.

Q: Does Урегит require regular blood tests or monitoring?

A: Yes, it is important that a healthcare professional monitor your progress during regular visits. Blood tests may be needed to check for potential unwanted effects, such as fluid and electrolyte imbalances.

Q: Can Урегит cause dizziness or lightheadedness?

A: Yes, this medicine may cause orthostatic hypotension (a drop in blood pressure when changing positions), which can lead to dizziness. Dizziness and lightheadedness are also listed as symptoms associated with fluid and electrolyte imbalance.

Q: Is there a maximum time frame for how long one can take Урегит?

A: There is no stated maximum time frame for the use of this medicine in the official documents. However, its use is typically managed based on a patient's individual needs, often moving to an intermittent schedule, and close medical supervision is required for continued use.

How should Урегит be stored and disposed of?

How to Store and Dispose of Урегит (Etacrynic Acid)

The storage and disposal instructions for Урегит are officially mandated to maintain the medicine's integrity and ensure safety.

Formulation Storage Requirement Disposal Requirement
Oral Tablets Store at Controlled Room Temperature, 20°C to 25°C, in a tightly closed container. Keep the tablets from freezing and avoid storage in humid areas. Do not flush down the toilet or drain. Utilize local drug take-back programs for unused or expired product.
Injection (Powder) The powder is stable at room temperature. The reconstituted solution must be discarded after 24 hours and must not be used if hazy. Follow the institution's official waste handling procedures.

All forms of this medicine must be kept out of the reach of children. If tablets are broken, avoid breathing any resultant dust.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Урегит found in:

A-Z Index: